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Abstract Familial hypobetalipoproteinemia (FHBL) sub-
jects may develop fatty liver. Liver fat was assessed in 21
FHBL with six different apolipoprotein B (apoB) trunca-
tions (apoB-4 to apoB-89) and 14 controls by magnetic reso-
 
nance spectroscopy (MRS). Liver fat percentages were 16.7 
 

 
11.5 and 3.3 
 

 
 2.9 (mean 
 

 
 SD) (
 
P
 
 
 

 
 0.001). Liver fat per-
centage was positively correlated with body mass index,
waist circumference, and areas under the insulin curves of 2 h
glucose tolerance tests, suggesting that obesity may affect
the severity of liver fat accumulation in both groups. De-
spite 5-fold differences in liver fat percentage, mean values
for obesity and insulin indexes were similar. Thus, for simi-
lar degrees of obesity, FHBL subjects have more hepatic
fat. VLDL-triglyceride (TG)-fatty acids arise from plasma
and nonplasma sources (liver and splanchnic tissues). To as-
sess the relative contributions of each, [
 
2
 
H
 
2
 
]palmitate was
infused over 12 h in 13 FHBL subjects and 11 controls. Iso-
topic enrichment of plasma free palmitate and VLDL-TG-
palmitate was determined by mass spectrometry. Non-
plasma sources contributed 51 
 

 
 15% in FHBL and 37 
 

 
13% in controls (
 
P
 
 
 

 
 0.02). Correlations of liver fat per-
centage and percent VLDL-TG-palmitate from liver were 
 
r
 
 
 

 
0.89 (
 
P
 
 
 

 
 0.0001) for FHBL subjects and 
 
r
 
 
 

 
 0.69 (
 
P
 
 
 

 
0.01) for controls.  Thus, apoB truncation-producing mu-
tations result in fatty liver and in altered assembly of VLDL-
 
TG.
 
—Schonfeld, G., B. W. Patterson, D. A. Yablonskiy, T. S. K.
Tanoli, M. Averna, N. Elias, P. Yue, and J. Ackerman.
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Familial hypobetalipoproteinemia (FHBL) is a geneti-
cally heterogeneous Mendelian dominant condition (1)
 
that may be divided into at least four genetic subclasses: 
 
a
 
)
mutations of 
 
APOB
 
 (40 truncation-producing mutations
ranging from apoB2 to apoB-89) (2–5); 
 
b
 
) FHBL linked to
chomosome 3p21 (6, 7); 
 
c
 
) LDL receptor-deficient famil-
ial hypercholesterolemia in which a “cholesterol lowering
gene” is linked to chomsome 13p (8, 9); and 
 
d
 
) FHBL
linked to none of the above loci (Schonfeld, unpublished
observations). Most FHBL subjects are heterozygous and
are usually asymptomatic, but an undetermined propor-
tion have nonalcoholic fatty liver (NAFL) (5, 10–18).
Since in several previous studies of liver fat the genetic
classification of reported subjects was not specified, and in
all studies a semi-quantitative measure of liver fat (ultra-
sound) was used, it is not clear how the specific genetic
basis of FHBL affects either the frequency or severity of
the fatty liver. We now report on liver fat in our group of
subjects with the heterozygous form of FHBL due to 
 
APOB
 
defects using a noninvasive quantitative method, mag-
netic resonance spectroscopy (MRS) (19–22). Since NAFL
in humans is often associated with obesity and/or insulin
resistance (23), we also measured indexes of obesity and
insulin resistance in our FHBL subjects.
VLDL particles are assembled in liver from several apo-
lipoproteins, the most important in humans being apoB-
100, and the three major lipid classes: triglycerides (TG),
cholesterol, and phospholipids. The TG component of
VLDL particles is assembled from glycerol and fatty acids
(FA). The FA incorporated into VLDL-TG may be derived
from more than one source. Circulating nonesterified
fatty acids (NEFA) may arise from lipolyzed adipose tissue
 
Abbreviations: ER, endoplasmic reticulum; FA, fatty acids; FHBL,
familial hypobetalipoproteinemia; MRS, magnetic resonance spectros-
copy; NAFL, nonalcoholic fatty liver; NEFA, nonesterified fatty acids;
PR, production rate; TG, triglyceride; TTR, tracer/tracee ratio; Ra,
rate of appearance.
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TG, and are transported in plasma complexed to albu-
min. FA also may arise from lipolyzed chylomicron-TG or
VLDL-TG. These FAs are removed by liver and esterified
into TG that may be assembled into VLDL-TG for export.
FA may also be derived within liver by de novo synthesis
(24–26). Mature VLDL particles are assembled in two
steps (27): complexes form between lipids and apoB in
the rough endoplasmic reticulum (ER) to form a primary
VLDL particle, and these fuse with a separately formed
“apoB-free” lipid particle fashioned in smooth ER (28).
However, the relative contribution of plasma FA and non-
plasma FA sources to the TG in these precursor particles
and their subsequent assembly into VLDL-TG in vivo has
not been studied in humans with FHBL. We hypothesized
that there would be a positive correlation between the
amount of fat detectable in liver by MRS and the relative
contribution of nonplasma fatty acids to VLDL-TG. To as-
sess the contribution of nonplasma sources, [
 
2
 
H
 
2
 
]palmi-
tate was infused as a representative fatty acid, and the ex-
tent of isotopic dilution between plasma [
 
2
 
H
 
2
 
]palmitate
and VLDL-TG palmitate was assessed by a compartmental
model. Some of the results have been presented in ab-
stract form (29, 30).
METHODS
 
Study subjects and protocols 
 
The Washington University Human Studies Committee Stud-
ies approved our protocols, and informed consent procedures.
No subjects were acutely ill or taking any medications known to
affect lipid metabolism. None were diabetic, although a few had
BMIs 
 

 
 30. Controls were either unaffected married members of
the FHBL families or unrelated volunteers. There was no history
of hepatitis or alcohol abuse. Liver chemistry profiles were nor-
mal. The controls to the FHBL subjects were matched with re-
spect to mean age, gender, and indexes of obesity. For both the
MRS and infusion studies, subjects were instructed not to change
their diets and to abstain from ethanol for at least 1 week before
the studies. A dietician interviewed a subset of patients about di-
etary intake using a 7-day diary. MRS studies were performed af-
ter fasting overnight (10–12 h) in those cases where [
 
2
 
H
 
2
 
]palmi-
tate infusion studies were not performed. In those cases where
infusions were done, the infusions were performed first, then
subjects ate breakfast at 7–8 AM and underwent the MRS exam
between 1–5 PM. To assess the effects of the time of day on MRS
measurements five determinations of liver fat percentage by
MRS were performed as indicated in Table 4 over a 24 h period
in three FHBL and three control subjects. Meals were eaten as
follows: breakfast at 9 AM, lunch at 1 PM, and dinner at 6 PM. To
assess any longer-term changes, the liver fat percentage in five
FHBL subjects was examined following an overnight fast over a
period ranging from 18 days to several months.
 
Magnetic resonance spectroscopy 
 
All MRS data were collected on a 1.5T Siemens Magneton Vi-
sion scanner (Siemens, Erlanger, Germany). A localized volume
MR technique based on a double spin echo PRESS sequence
(31) without water suppression was used. Accurate voxel localiza-
tion was achieved by utilizing specially designed numerically op-
timized RF pulses (32). This not only improved voxel localization
but also almost doubled the signal-to-noise ratio by improving
 
voxel profile. An outer volume suppression technique was used
to eliminate possible contamination of the weak signal from liver
fat by very strong signals from subcutaneous fat outside the vol-
ume of interest. Prior to volume localized data acquisition, an
imaging protocol was performed that included acquisition of an-
atomical images and positioning of the spectroscopic voxel in
the area of the liver. Ten signal averages were obtained over a 20 s
period. Both the anatomical images and the spectroscopic data
were obtained while subjects held their breath. Three 2 
 

 
 2 
 

 
 2
cm
 
3
 
 voxels were examined in each subject. The coefficient of
variation of replicate values of the triplicate determinations for 3
voxels was 1.5% (n 
 

 
 31 MRS examinations). An example of ana-
tomical image used for positioning of voxels is provided in 
 
Fig. 1
 
,
inset. Two data sets with spin echo times 23 ms and 53 ms were
obtained from each voxel and used to evaluate the spin density
for fat and water contributions. The MRS liver fat percentage was
reported as the spin density of the aliphatic 
 
1
 
H signal divided by
the sum of the spin densities of aliphatic plus water 
 
1
 
H signals.
Bayesian probability theory (33) was used for time-domain
data analysis. The water and fat time-domain signals were each
modeled as a sum of exponentially decaying sinusoids. The am-
plitude and frequency of each sinusoid were optimally estimated
(along with the decay rate constant and phase). All frequencies,
i.e., chemical shifts, were measured relative to the principal wa-
ter 
 
1
 
H resonance, which was referenced as zero Hz. Typical fre-
quency-domain linewidths of the water signal were in the range
30–35 Hz. Examples of 
 
1
 
H-MRS frequency domain spectra are
provided in Fig. 1. The lipid signal resulted from multiple chem-
ically shifted 
 
1
 
H resonances corresponding to methyl and meth-
ylene groups occupying different positions on lipid molecules
with frequencies found in the range 
 

 
140 Hz to 
 

 
245 Hz (0.9–
2.4 ppm) with major peak at about 
 

 
220 Hz (
 

 
1.3 ppm) corre-
sponding to methylene groups in (CH
 
2
 
)n chains (19, 21, 34).
The sum total of the resonance amplitudes from both the methyl
and methylene groups were used for calculation of hepatic tri-
glyceride content. The residual of all modeling was always less
than 1%.
To assess the comparability of chemical measurements of liver
triglycerides and liver fat measured by MRS, the excised livers of
six mice, wild-types and FHBL mimics engineered to harbor the
apoB38.9 truncation (10), were examined by MRS using the
same scanner and the same pulse sequence as for human studies.
Lipids were extracted (35) and TG quantified by an enzymatic
method (Wako, Richmond, VA). Fat content determined by
chemical analysis in these mice ranged from 7 mg to 45 mg TG/
gram wet liver. The regression of weight percentage liver TG
(chemical) on MRS liver fat percentage was y 
 

 
 0.807x, 
 
R
 
2 
 

 
0.986.
 
VLDL-TG metabolic studies
 
 Subjects were admitted to the Washington University General
Clinical Research Center after a 10-h fast at about 6 PM. Intrave-
nous catheters were inserted into the antecubital fossae of both
arms, one for infusion, the other for venous blood sampling. [2,2-
 
2
 
H
 
2
 
]palmitate (Cambridge Isotope Laboratories, Andover MA)
infusions contained 0.341 g of potassium palmitate/100 ml of
25% sterile human serum albumin (molar ratio 
 

 
 3.1), and were
infused at 0.04 
 

 
mol/kg/min for 12 h using an Ivac pump.
[1,1,2,3,3-
 
2
 
H
 
5
 
]glycerol (Cambridge Isotope Laboratories) was dis-
solved in sterile 0.9% saline and administered as a bolus (75
 

 
mol/kg). Blood samples were obtained at 0, 5, 15, 30, and 60
min, then at 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 12 h for the determi-
nation of plasma and VLDL-TG derived glycerol and palmitate
isotopic enrichment. Plasma was separated by centrifugation
within 30 min of sample collection. Two milliliters of fresh plasma
was overlaid with d 
 

 
 1.006 g/ ml EDTA-saline, spun in a 50.4 Ti
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rotor at 40,000 rpm in a Optima LE80K ultracentrifuge (Beck-
man Instruments, Palo Alto, CA), and the VLDL fraction recov-
ered by tube slicing. Remaining plasma was frozen at 
 

 
70
 

 
C.
 
Isotopic analyses 
 
Procedures to process plasma and VLDL-TG and measure the
tracer/tracee ratio (TTR) of glycerol and palmitate have been
previously reported (36, 37). The TTR of the heptafluorobutyryl
derivative of glycerol (m
 

 
5/m
 

 
0 isotopomer ratio) and palmi-
tate methyl ester (m
 

 
2/m
 

 
0 isotopomer ratio) were measured
by electron impact ionization gas chomatography/mass spec-
trometry (GC/MS) on a Hewlett-Packard (Palo Alto, CA) 5973
GC/MS system (37). Instrumental response was calibrated using
standards of known isotopic enrichment.
 
Kinetic modeling
 
The VLDL-TG metabolic kinetics using a bolus of [
 
2
 
H
 
5
 
]glyc-
erol and an infusion of [
 
2
 
H
 
2
 
]palmitate was assessed using a com-
partmental model (36–38). Kinetic parameters were indepen-
dently determined for glycerol and palmitate tracers. The model
incorporates the time course of plasma glycerol and palmitate
tracers, provides an excellent fit to the VLDL-TG glycerol/palmi-
tate TTR time course, and provides an estimate of the fractional
contribution from plasma versus nonplasma sources of VLDL-TG
palmitate by accounting for the extent of isotopic dilution be-
tween the plasma palmitate and VLDL-TG. Although hepatic de
novo lipogenesis may account for 
 

 
30–50% of the palmitate ap-
pearing in VLDL-TG during periods of high carbohydrate feed-
ing (39, 40), de novo lipogenesis can be virtually undetectable
and accounts for less than 5% of VLDL-TG palmitate during basal
fasting conditions such as those in our study (39–42). Thus, the
isotopic dilution during fasted conditions is primarily due to the
contribution from preformed palmitate from nonplasma sources,
e.g., the splanchnic bed and liver. The VLDL-TG production rate
(PR) was the product of the fractional catabolic rate (FCR) de-
termined using the glycerol bolus tracer and VLDL-TG concen-
tration. Compartmental modeling was performed using the
SAAM II program (SAAM Institute, University of Washington, Se-
attle). The compartmental model accounts for any isotopic dilu-
tion of glycerol in liver and the recycling of tracer glycerol into a
nonplasma glycerol pool that turns over and contributes to
VLDL-TG production, causing the “tail” of the VLDL-TG glycerol
enrichment to flatten out at the end. The model determines the
true VLDL-TG FCR by resolving this recycling process, and thus
the VLDL-TG production rate is determined by FCR 
 

 
 pool size.
The rate of appearance (Ra) of palmitate into plasma was
used as an index of the rate of whole-body lipolysis and delivery
of fatty acids to the liver for VLDL-TG production. Palmitate Ra
was evaluated using the steady-state Steele equation (43) as mod-
ified for use with stable isotopes (44): Ra 
 

 
 I/TTR, where I 
 

 
rate of tracer palmitate infusion (
 

 
mol/kg/min).
 
Indexes of obesity and insulin resistance 
 
Body mass (kg) and height (m) were measured and the BMI
(height/body mass
 
2
 
) calculated. Waist and hip circumferences
were measured, and waist to hip ratios were calculated. Two-hour
oral glucose tests using 75 gm of glucose and measurements of
plasma glucose and insulin were obtained using standard meth-
ods after the MRS study in the morning or on a different morn-
ing a few days later. AUC for glucose and insulin and a fasting
Fig. 1. 1H-magnetic resonance frequency domain spectra derived from hepatic voxels. Main peak in both graphs belongs to water signal
and smaller peaks belong to triglycerides. Fat content in familial hypobetalipoproteinemia (FHBL) subjects is 18% and in control subject is
2%. The inset shows a magnetic resonance image of liver. The sites of three voxels are indicated by the boxes. The areas on the left side of
the picture covered by the wide lines (saturation pulses) consist mostly of subcutaneous fat; these signals were suppressed so as not to con-
tribute to the intrahepatic fat signals.
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HOMA index for insulin resistance were calculated using fasting
values of glucose and insulin (45).
 
Statistical analysis 
 
Statistical analyses used SAS/STAT (SAS Institute, Gary, NC).
Pearson or Spearman correlation coefficients were used as ap-
propriate. Log transformation of liver fat percentage was used
since it was not normally distributed. The Chi-square test was
used to compare sex differences among groups, and the Kruskal-
Wallis to compare age differences. The ANOVA (Duncan’s multi-
ple range test) was used to compare means of subject groups
(
 
P
 
 
 
	
 
 0.01). Multivariate stepwise regression was used with MRS
liver fat percentage or log liver fat percentage as the dependent
variable. Male gender was assigned a value of zero and females of
one. Results shown are mean 
 


 
 SD.
 
RESULTS
 
Study subjects 
 
Demographic characteristics are provided in 
 
Table 1
 
.
Twenty-one simple heterozygous subjects and one com-
pound heterozygous female (with an apoB
 
40/89
 
 genotype)
participated. They represented various apoB truncations
(
 
Table 2
 
). The original references describing the muta-
tions are provided in Table 2. Table 2 also lists the subjects
who participated in the MRS study, in the palmitate infu-
sion study, or in both.
The eight families from which the 22 affected subjects
volunteered for the protocols form part of a larger group
of 14 St. Louis FHBL families. The seventy-one additional
FHBL affected subjects who did not undergo MRS analysis
resembled the 22 FHBL subjects who did, with respect to
lipoprotein levels, age, gender, and indexes of body
weight (Table 1). The 22 FHBL subjects and the 15 con-
trols differed with respect to apoB and LDL-cholesterol
(LDL-C) by definition but not with respect to age, gender
and indexes of insulin resistance or obesity (Table 1).
 
Fatty liver 
 
Mean MRS liver fat percentage of FHBL subjects were
5-fold higher than in controls (16.7 
 


 
 11.5 vs. 3.3 
 


 
 2.9,
respectively, 
 
P
 
 
 

 
 0.001) (Table 2). However, there were
substantial overlaps between control and the lower FHBL
values. Log liver fat percentage was significantly positively
correlated with BMI, waist, and insulin AUC in FHBL sub-
jects, and was higher in male than female FHBL subjects.
A similar pattern of correlations was seen in controls (
 
Ta-
ble 3
 
). On multivariate analysis of the combined groups,
significant predictors of liver fat percentage were gender,
BMI, and LDL-C (
 
R
 
2
 
 
 

 
 0.44, 
 
P
 
 
 

 
 0.002). For the FHBL
group, gender and LDL-C were the most important pre-
dictors (
 
R
 
2
 
 
 

 
 0.65, 
 
P
 
 
 
 0.004). Thus, for a given BMI or
waist circumference the liver fat content of FHBL subjects
were higher than controls.
TABLE 1. Subject characteristics
FHBL Studied 
Group
MRS Control
Group
FHBL Control
Group
Age (years) 44 
 16 40 
 14 40.7 
 19.6
Number (gender) 22 16 71
(11 M:11 F) (8 M:8 F) (47 M:24 F)
BMI (kg/m2) 26 
 4 26.8 
 4.7 25.9 
 6.2
Waist (cm) 90 
 13 87 
 17
Waist/hip ratio 0.87 
 0.09 0.82 
 0.09
Total TG (mg/dl) 60.4 
 58.1 55.5 
 39.8 68.4 
 47.1
VLDL TG (mg/dl) 48.3 
 54.2 42.5 
 33.5 40.3 
 31.3
Total cholesterol (mg/dl) 109 
 29 184 
 31 108.2 
 27.3
VLDL-cholesterol (mg/dl) 10 
 12 15 
 14 10.0 
 13.6
LDL-cholesterol (mg/dl) 44 
 18a 117 
 26a 42.3a 
 18.7
HDL-cholesterol (mg/dl) 55 
 20 51 
 14 52.1 
 13.7
ApoB (mg/dl) 26 
 15a 80 
 17a 34.5a 
 17.1
ApoA-I 
 SD (mg/dl) 127.9 
 30.9 117.7 
 21.1 135.8 
 25.2
AUC-glucose (mg/dl/min) 660 
 317 452 
 359
AUC-insulin (/ml/min) 605 
 255 381 
 340
Fasting HOMA 1.39 
 0.99 1.32 
 1.06
Mean 
 SD.
a Comparisons were made among means of the three groups with
Duncan’s multiple range test, overall P level  0.01. For all other com-
parisons P  0.2.
TABLE 2. Fraction of VLDL-TG-palmitate derived from 
hepatic stores
Study Subjects
ApoB 
Genotype
References 
to
Original
Description
VLDL-TG-Palmitate
Derived from 
Nonplasma 
Palmitate
(Model)
Liver Fat
Percentage
(MRS)
Affected
T1 B-4/B-100  (56) 0.76 31.1
T2 B-4/B-100  (56) 0.62 18.9
T10 B-4/B-100  (56) 0.64 19.4
T11 B-4/B-100  (56) 0.51 18.0
T12 B-4/B-100  (56) 0.38 ND
T16 B-4/B-100  (56) 0.44 2.3
MR36 B-4/B-100  (56) ND 3.6
MR32 B-9/B-100  (57) ND 17.2
MR33 B-9/B-100  (57) ND 13.2
MR35 B-9/B-100  (57) ND 17.2
MR52 B-29/B-100  (58) ND 36.5
MR26 B-31/B-100  (59) ND 8.4
T17 B-52/B-100  (60) 0.58 17.3
T18 B-52/B-100  (60) 0.22 4.4
T21 B-52/B-100  (60) 0.38 1.6
T22 B-52/B-100  (60) 0.43 3.9
MR31 B-52/B-100  (60) ND 6.7
T13 B54.8/B-100  (61) 0.40 1.7
MR29 B-75/B-100  (62) ND 14.1
T3 B-40/B-89  (63) 0.71 31.7
T19 B-89/B-100  (63) 0.52 24.1
T20 B-89/B-100  (63) 0.53 15.1
Mean 
 SD 0.51 
 0.15 16.7 
 11.5
Controls
T4 B-100/B-100 0.34 ND
T5 B-100/B-100 0.38 3.7
T6 B-100/B-100 ND 3.4
T7 B-100/B-100 0.34 2.3
T8 B-100/B-100 0.26 1.2
T9 B-100/B-100 0.33 2.2
T14 B-100/B-100 0.45 9.3
T15 B-100/B-100 0.30 0.5
T23 B-100/B-100 0.22 1.1
T24 B-100/B-100 0.43 7.3
T25 B-100/B-100 0.40 1.0
T26 B-100/B-100 0.32 0.4
MR41 B-100/B-100 ND 1.1
MR46 B-100/B-100 ND 1.8
MR47 B-100/B-100 ND 5.4
MR48 B-100/B-100 ND 7.3
Mean 
 SD 0.37 
 0.13 3.3 
 2.9
P 0.002 0.001
ND, not done.
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Liver contents varied over 24 h by 10% (Table 4).
Liver contents in FHBL subjects measured over several
months varied by 30% but levels remained high with
each determination (Table 5).
[2H2]palmitate infusions: palmitate fluxes, 
VLDL-TG assembly
Plasma palmitate TTR achieved plateau values within
2 h and remained relatively constant thereafter (Fig. 2,
upper curves). Mean palmitate flux rates (Ra) were identi-
cal in control (2.19 
 0.53 mol/kg/min) and FHBL sub-
jects (2.19 
 0.67 mol/kg/min; P  0.81).
VLDL-TG palmitate TTR approached a plateau around
10 h (Fig. 2, lower curves). Nonplasma sources contrib-
uted 37 
 13% of VLDL-TG palmitate in control subjects
and 51 
 15% in FHBL subjects (P  0.002) (Table 2).
There were significant positive correlations between the
relative contribution of nonplasma sources and liver fat
percentage for FHBL (r  0.890, P  0.0001) and for the
control (r  0.691, P  0.018) (Table 3, Fig. 3). However,
the linear regression lines differed for the two groups,
even when one seeming outlier control subject was omit-
ted from the calculation (Fig. 3). The slope of the line for
the control group did not differ from zero, but the slope
for FHBL did differ from zero. On multivariate analysis,
the fraction of VLDL-TG-palmitate derived from non-
plasma sources was the most important determinant of
liver fat content for FHBL subjects. This was not true for
controls.
The VLDL-TG FCR, determined with the bolus injected
glycerol tracer, was not significantly different between
FHBL subjects and controls (Table 6). However, the ap-
parent VLDL-TG FCR determined with the infused palmi-
tate tracer was significantly slower for FHBL subjects com-
pared with controls (Table 6). These differences between
TABLE 3. Correlation coefficient between liver fat content and the 
indicated parameters
Log (Liver Fat Percentage)
versus FHBLL
Log (Liver Fat Percentage)
versus Controls
Gendera 0.45b,c (0.43) 0.62c (0.63c)
BMII 0.49b (0.51c) 0.60b (0.60b)
Waist 0.48b (0.59c) 0.73c (0.71b)
AUC-insulin 0.49b (0.46) 0.30 (0.35)
Fraction VLDL-TG 
palmitate derived
from nonplasma
sources
0.77e (0.89e) 0.50 (0.69b)
VLDL-TG glycerol
production rate
0.01 (0.08) 0.16 (0.27)
Pearson coefficiencies are shown, Spearman correlation coeffi-
ciencies are listed in parentheses.
a Gender was coded as 0 for male, and 1 for female.
b Statistically significant at P  0.05.
c Statistically significant at P  0.02.
d Statistically significant at P  0.01.
e Statistically significant at P  0.0001.
TABLE 4. Diurnal variation in liver fat contents
Patient Number Status Date of Study Time Mean Fat Percentage SD
T26 control 11/17/01 7 AM 2.8 0.5
12 PM 0.9 0.9
5 PM 0.7 0.5
10 PM 0.6 0.6
7 AM 0.8 0.6
T8 control 01/12/02 7 AM 1.9 0.3
12 PM 1.1 0.3
5 PM 0.9 0.2
10 PM 0.9 0.4
7 AM 0.9 0.3
T9 control 01/12/02 7 AM 8.3 9.0
12 PM 2.9 0.9
5 PM 5.1 1.4
10 PM 5.3 7.0
7 AM 1.8 0.6
MR35 apoB-9 03/23/02 7 AM 27.8 1.0
12 PM 34.7 1.4
5 PM 29.8 2.1
10 PM 30.4 2.5
7 AM 29.0 1.3
T2 apoB-4 04/27/02 7 AM 21.5 1.1
12 PM 20.9 0.4
5 PM 21.2 0.6
10 PM 21.4 3.4
7 AM 21.9 1.3
MR36 apoB-4 05/18/02 7 AM 1.6 0.6
12 PM 2.4 0.5
5 PM 1.8 0.8
10 PM 1.1 0.8
7 AM 2.1 0.1
Results are means and SD of liver fat percentage determinations in
three nonoverlapping voxels.
TABLE 5. Liver fat contents of FHBL subjects measured several 
months apart
FHBL 
Subject
ApoB 
Truncation
Date of
MRS Analysis
Liver Fat 
Percentage
T1 B-4 10/08/00
06/09/01
34.1
47.7
T2 B-4 10/08/00
06/09/01
04/27/02
33.1
30.9
21.5
T10 B-4 10/22/00
06/09/01
22.5
29.4
T11 B-4 10/22/00
06/09/01
18.5
24.9
Fig. 2. Time course for enrichment of plasma and VLDL-TG
[2H2]palmitate. The tracer/tracee ratio of plasma (solid symbols)
and VLDL-TG (open symbols) is displayed for control subjects (left
panel) and FHBL subjects (right panel). Results shown are group
means 
 SEM.
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bolus glycerol and infused palmitate have been previously
noted (37). VLDL-TG PR computed from the glycerol
data tended to be lower in FHBL. VLDL-TG PR were not
computed for the infusion palmitate data because we be-
lieve them not to reflect the “true” production rates, for
reasons set out in the discussion.
DISCUSSION
Mean MRS liver fat percentage contents of FHBL sub-
jects were 5-fold higher than controls (Table 2). If two
standard deviations above the mean for the controls is
used as a cut point, 60% of APOB-defective FHBL sub-
jects had fatty livers. These MRS data provide at least an
initial estimate of the prevalence of fatty liver in FHBL of
this genotype, since the 22 FHBL subjects surveyed for
liver fat were drawn from some of the same families as the
71 FHBL subjects whose liver fat contents were not deter-
mined, and resembled them in a number of ways (Table
1). It is worth pointing out that the severity of fatty liver is
less in subjects with another genetic form of FHBL that
linked to chomosome p321 (6, 7) (Schonfeld, et al., un-
published observations). We have also documented that
the apoB-100 and VLDL-TG production rates of the 3p21
subjects are less severely depressed than those of subjects
bearing truncations of apoB (36, 38). These data suggest
that the different FHBL genotypes may result in different
phenotypes with respect to hepatic steatosis and VLDL ki-
netics.
Liver fat contents vary relatively little over 24 h in those
with high levels of liver fat. Variations are larger in those
subjects with low fat contents (Table 3). There are at least
three potential sources of variation in these studies. First,
based on analyses of signal to noise ratios, the minimum
amount of fat that can be accurately quantified is 0.5%.
Thus, small changes in the absolute fat contents of livers
containing small amounts of fat may result in large per-
centage variations. Second, the variations may reflect real
regional differences in fat contents of the liver. This is
shown in Table 4, where mean values for the three adja-
cent, but noncontiguous voxels measured are provided
(see SDs). Intrahepatic variation in fat content is not sur-
prising since it is frequently seen even in the very small
volumes of tissue obtained on liver biopsy. Further, the lo-
cation of voxels within the liver is unlikely to be identical
at different times of MRS despite our best attempts, be-
cause the depths of respiratory excursions may vary. Fi-
nally, there may be “real” changes over longer periods of
time (Table 4). Nevertheless, the relative stability of the
data collected over 24 h supports the validity of perform-
ing measurements at different times of the day. The MRS
measurements taken several months apart show that,
while the extent of fatty liver may vary, the levels remain
high on repeated assessments. The determinants of
longer-term changes remain to be identified.
Subjects with apoB truncations may be susceptible to
fatty livers for several reasons. The major cause is the pres-
Fig. 3. Regression of tracer-derived estimate of the contribution of liver fat to VLDL-TG-palmitate on liver fat percentage content as mea-
sured by MRS in FHBL and controls. If the control subject in the lower right hand corner of the figure is omitted, the regression becomes
y  31.32x7.82, R2  0.57.
TABLE 6. VLDL-TG kinetics
VLDL-TG FCR VLDL-TG PR
Subjects VLDL-TG Glycerol Palmitate Glycerol
mg/dl pools/h mg/dl/h
FHBL
Mean 
 SD 29 1.00 0.37 24.4
23 0.57 0.15 16.2
Controls
Mean 
 SD 47 1.21 0.59 35.7
46 0.77 0.31 14.9
P 0.217 0.501 0.021 0.123
Palmitate tracer significantly different from glycerol trace P  0.05.
 by guest, on August 17, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
476 Journal of Lipid Research Volume 44, 2003
ence of the apoB truncation mutations, and the ensuing
reduced capacity of the hepatic VLDL-TG exporting sys-
tem because the gene defects produce several alterations
in lipoprotein transport: a) reduced secretion rates of
apoB-100 (36, 46, 47); b) reduced rates of secretion of
some of the apoB truncations (48); and c) limited capacity
of short truncations (apoB-40) to transport TG (49–52).
Despite these defects of the apoB vehicle, the liver VLDL
exporting system is able to transport more TG than would
be expected from the normal functioning of only one al-
lele of apoB. Smaller numbers of particles and smaller
than normal sized particles must be able carry more TG
per particle than under normal conditions. However, this
adaptation is clearly insufficient to prevent TG accumula-
tion in liver.
Several factors affect the amount of fat accumulated in
liver (23). These did not account for the differences be-
tween the amounts of liver fat in our FHBL subjects and
controls. The two groups did not differ in their intakes of
nutrients or alcohol, nor did they differ with respect to in-
dexes of generalized or abdominal obesity, or insulin resis-
tance as measured during an oral glucose tolerance test.
To the extent that the oral test underestimates “true” insu-
lin resistance (compared with the “gold standard”, the hy-
perinsulinemic euglycemic clamp method), we may have
missed subtle abnormalities in insulin sensitivity. Thus,
the question of insulin resistance in FHBL remains some-
what open. Further, differential rates of flux of free fatty
acids to liver could not account for the hepatosteatosis,
because rates of flux of fatty acid to liver were similar in
the FHBL and control groups. (Rates of palmitate appear-
ance into plasma were similar between groups and the
rate of disposal equals the rate of appearance at metabolic
steady state). Finally, rates of hepatic VLDL-TG produc-
tion in FHBL subjects were the same or decreased com-
pared with controls (36, 38), probably reflecting de-
creased rates of hepatic fatty acid synthesis, as illustrated
in the apoB-38.9- and apoB-27.6-bearing mice (51, 52).
Thus, the apoB defects per se played major roles in the
hepatosteatosis.
The amount of hepatic fat present varies widely be-
tween various FHBL subjects. We have also demonstrated
variability in the amount of liver fat accumulated in genet-
ically engineered mice with apoB38.9 and apoB27.6 trun-
cations (51–53). In part, this variability may be due to
countervailing processes that may limit fat accumulation.
These mice manifest fatty livers, along with a concomi-
tant compensatory down-regulation of hepatic fatty acid
synthesis and decreased expression of several fatty acid
synthetic enzymes and of SREBP-1c, the responsible
transcription factor (53). Thus, the amount of TG accu-
mulating in liver is probably modulated by a number of
genes. One would predict that “genetic background” on
which the apoB truncation is superimposed would affect
the degree of hepatic fat accumulation, but this remains
to be determined.
The use of palmitate infusions to study the contribution
of nonplasma FA sources to VLDL-TG assembly assumes
that palmitate is an adequate tracer of other FAs. In pre-
liminary experiments, B. Patterson and S. Klein (unpub-
lished observations) infused five 2H-labeled FAs (myris-
tate, palmitate, stearate, oleate, and linoleate) in seven
healthy subjects. The Ra of palmitate as a percentage of
the sum of all five FAs was constant under basal fasting
conditions, and when whole body lipolysis was stimulated
or inhibited. Furthermore, the percentage of palmitate
and oleate compositions of plasma TG (33% and 41%, re-
spectively) was similar to the percentage composition of
plasma NEFA (28% and 39%, nonesterified palmitate and
oleate, respectively). Therefore, we believe palmitate to be
an adequate tracer for our purposes.
We recently validated the use of stable isotopically la-
beled glycerol and palmitate tracers to determine the
turnover rate of VLDL-TG (37). The two tracers gave the
same VLDL-TG FCR when given simultaneously as a bo-
lus, and the metabolic kinetics were analyzed by the com-
partmental model that could resolve VLDL turnover from
tracer recycling. However, the apparent FCR using a con-
stant infusion of labeled palmitate was substantially lower
than the “true” FCR obtained using a bolus of glycerol, be-
cause the tracer-recycling pathway cannot be resolved with
the infused palmitate tracer. The same relationship was
observed with the subjects in this study (Table 6). The
“true” VLDL-TG FCR measured with the bolus glycerol
tracer was not significantly different between FHBL and
control subjects, whereas the “apparent” VLDL-TG FCR
measured with the infused palmitate was significantly
slower in the FHBL subjects who had elevated hepatic
lipid levels. The present study confirms our earlier specu-
lation (37) that the VLDL-TG time course using an infu-
sion of palmitate appears slower than the “true” VLDL-TG
turnover rate, because palmitate tracer is taken up into a
hepatic lipid pool that turns over slowly and contributes a
“slow” pathway for tracer incorporation into VLDL-TG
palmitate. This intrahepatic pathway for fatty acid tracer
recycling causes an attenuation of the VLDL-TG palmitate
time course kinetics over how it would appear in the ab-
sence of this slowly turning over hepatic lipid pool. It is
likely that the infused palmitate tracer may in fact provide
more information about the turnover rate of hepatic lipid
stores than it does VLDL-TG.
The presence of fatty liver due to a known genetic cause
in our FHBL subjects provided the opportunity to exam-
ine the relationship between the amounts of fat present in
liver and the contributions of nonplasma sources of fatty
acids to the assembly of VLDL-TG. Non-plasma sources
provided a larger proportion of fatty acids in FHBL sub-
jects than in controls. In addition, the strong correlation
observed between the percentage of liver fat by MRS and
the contribution of nonplasma sources to VLDL-TG as-
sembly in FHBL subjects strongly suggests that hepatic
lipid rather than other splanchnic stores contributes a ma-
jor portion of nonplasma palmitate in FHBL subjects. Our
results for the relative contribution of hepatic fatty acids
are compatible with early reports that used constant infu-
sions with radiolabeled palmitate (54, 55), and more re-
cent studies that used [13C4]palmitate (41); these range
from 0–69%. However, since hepatic fat contents were not
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reported in previous studies, correlations between liver fat
and VLDL-TG assembly were not determined. The quanti-
tative relationships between liver fat and the proportion-
ate contribution from nonplasma fatty acids differed be-
tween FHBL and control subjects (Fig. 3) such that there
was a relatively weak correlation between the percentage
of liver fat and the portion of VLDL-TG palmitate derived
from nonplasma sources in control subjects. This suggests
that splanchnic lipid stores rather than hepatic fat may
provide a greater portion of fatty acids for VLDL-TG pro-
duction in this group. It remains to be seen whether the
quantitative relationship established here for FHBL exists
also in other forms of fatty liver, e.g., that associated with
obesity and/or insulin resistance.
The authors appreciate the cooperation of our study subjects
and the interactions of Jackie Dudley RN and Sherry Banez-
Muth RN with them. We are grateful to Tom Kitchens for ex-
pert technical assistance, to G. Larry Bretthorst for help with
the Bayesian probability theory data analysis, to Xiaobo Lin
and Nobuhiro Sakata for the mouse fat determinations, and to
Mary Lou Rheinheimer and Patrick Doyle for preparation of
the manuscript. This research was supported by National Insti-
tutes of Health Grants HL-RO1-59515, HL-R37-42460, RR-
00036 (General Clinical Research Center), DK-56341 (Clinical
Nutrition Research Unit), RR-00954 (Biomedical Mass Spec-
trometry Resource) and R24-CA83060 (Small Animal Imaging
Resource Program).
REFERENCES
1. Kane, J. P. and R. J. Havel. 1995. Disorders of the biogenensis and
secretion of lipoproteins containing the B apolipoproteins. In The
Metabolic and Molecular Bases of Inherited Disease. C. R. Shriver,
A. L. Beaudet, W. S. Sly, and D. Valle, editors. McGraw-Hill Inc., New
York. 1853–1885.
2. Linton, M. F., R. V. Farese, Jr., and S. G. Young. 1993. Familial hy-
pobetalipoproteinemia. J. Lipid Res. 34: 521–541.
3. Schonfeld, G. 1995. The hypobetalipoproteinemias. Annu. Rev.
Nutr. 15: 23–34.
4. Welty, F. K., J. Ordovas, E. J. Schaefer, P. W. Wilson, and S. G.
Young. 1995. Identification and molecular analysis of two apoB
gene mutations causing low plasma cholesterol levels. Circulation.
92: 2036–2040.
5. Tarugi, P., A. Lonardo, C. Gabelli, F. Sala, G. Ballarini, I. Cortella,
L. Previato, S. Bertolini, R. Cordera, and S. Calandra. 2001. Phe-
notypic expression of familial hypobetalipoproteinemia in three
kindreds with mutations of apolipoprotein B gene. J. Lipid Res. 42:
1552–1561.
6. Yuan, B., R. Neuman, S. H. Duan, J. L. Weber, P. Y. Kwok, N. L. Sac-
cone, J. S. Wu, K. Y. Liu, and G. Schonfeld. 2000. Linkage of a gene
for familial hypobetalipoproteinemia to chromosome 3p21.1–22.
Am. J. Hum. Genet. 66: 1699–1704.
7. Neuman, R. J., B. Yuan, D. S. Gerhard, K. Y. Liu, P. Yue, S. Duan,
M. Averna, and G. Schonfeld. 2002. Replication of linkage of fa-
milial hypobetalipoproteinemia to chromosome 3p in six kin-
dreds. J. Lipid Res. 43: 407–415.
8. Hobbs, H. H., E. Leitersdorf, C. C. Leffert, D. R. Cryer, M. S.
Brown, and J. L. Goldstein. 1989. Evidence for a dominant gene
that suppresses hypercholesterolemia in a family with defective
low density lipoprotein receptors. J. Clin. Invest. 84: 656–664.
9. Knoblauch, H., B. Muller-Myhsok, A. Busjahn, L. Ben Avi, S. Bahr-
ing, H. Baron, S. C. Heath, R. Uhlmann, H. D. Faulhaber, S.
Shpitzen, A. Aydin, A. Reshef, M. Rosenthal, O. Eliav, A. Muhl, A.
Lowe, D. Schurr, D. Harats, E. Jeschke, Y. Friedlander, H. Schuster,
F. C. Luft, and E. Leitersdorf. 2000. A cholesterol-lowering gene
maps to chromosome 13q. Am. J. Hum. Genet. 66: 157–166.
10. Wishingrad, M., B. Paaso, and G. Garcia. 1994. Fatty liver due to
heterozygous hypobetalipoproteinemia. Am. J. Gastroenterol. 89:
1106–1107.
11. Hagve, T. A., L. E. Myrseth, E. Schrumpf, J. P. Blomhoff, B. Chris-
tophersen, K. Elgjo, E. Gjone, and H. Prydz. 1991. Liver steatosis
in hypobetalipoproteinemia. A case report. J. Hepatol. 13: 104–111.
12. Castellano, G., C. Garfia, D. Gomez-Coronado, J. Arenas, J. Manza-
nares, F. Colina, and J. A. Solis-Herruzo. 1997. Diffuse fatty liver in
familial heterozygous hypobetalipoproteinemia. J. Clin. Gastroen-
terol. 25: 379–382.
13. Ogata, H., K. Akagi, M. Baba, A. Nagamatsu, N. Suzuki, K.
Nomiyama, and M. Fujishima. 1997. Fatty liver in a case with het-
erozygous familial hypobetalipoproteinemia. Am. J. Gastroenterol.
92: 339–342.
14. Ahmed, A., and E. B. Keeffe. 1998. Asymptomatic elevation of ami-
notransferase levels and fatty liver secondary to heterozygous hy-
pobetalipoproteinemia. Am. J. Gastroenterol. 93: 2598–2599.
15. Mehta, N. N., and H. G. Desai. 1997. Persistent transaminase eleva-
tion due to heterozygous (familial) apolipoprotein B deficiency.
Indian J. Gastroenterol. 16: 158–159.
16. Tarugi, P., and A. Lonardo. 1997. Heterozygous familial hypobe-
talipoproteinemia associated with fatty liver. Am. J. Gastroenterol. 92:
1400–1402.
17. Tarugi, P., A. Lonardo, G. Ballarini, L. Erspamer, E. Tondelli, S.
Bertolini, and S. Calandra. 2000. A study of fatty liver disease and
plasma lipoproteins in a kindred with familial hypobetalipopro-
teinemia due to a novel truncated form of apolipoprotein B (APO
B-54.5). J. Hepatol. 33: 361–370.
18. Tarugi, P., A. Lonardo, G. Ballarini, A. Grisendi, M. Pulvirenti, A.
Bagni, and S. Calandra. 1996. Fatty liver in heterozygous hypobe-
talipoproteinemia caused by a novel truncated form of apolipo-
protein B. Gastroenterology. 111: 1125–1133.
19. Szczepaniak, L. S., E. E. Babcock, F. Schick, R. L. Dobbins, A.
Garg, D. K. Burns, J. D. McGarry, and D. T. Stein. 1999. Measure-
ment of intracellular triglyceride stores by H spectroscopy: valida-
tion in vivo. Am. J. Physiol. 276: E977–E989.
20. Ricci, C., R. Longo, E. Gioulis, M. Bosco, P. Pollesello, F. Masutti,
L. S. Croce, S. Paoletti, B. de Bernard, C. Tiribelli, and L. Dalla
Palma. 1997. Noninvasive in vivo quantitative assessment of fat
content in human liver. J. Hepatol. 27: 108–113.
21. Longo, R., P. Pollesello, C. Ricci, F. Masutti, B. J. Kvam, L. Bercich,
L. S. Croce, P. Grigolato, S. Paoletti, and B. de Bernard. 1995. Pro-
ton MR spectroscopy in quantitative in vivo determination of fat
content in human liver steatosis. J. Magn. Reson. Imaging. 5: 281–285.
22. Falck-Ytter, Y., Z. M. Younossi, G. Marchesini, and A. J. Mc-
Cullough. 2001. Clinical features and natural history of nonalco-
holic steatosis syndromes. Semin. Liver Dis. 21: 17–26.
23. Marchesini, G., M. Brizi, A. M. Morselli-Labate, G. Bianchi, E. Bu-
gianesi, A. J. McCullough, G. Forlani, and N. Melchionda. 1999.
Association of nonalcoholic fatty liver disease with insulin resis-
tance. Am. J. Med. 107: 450–455.
24. Brown, A. M., D. Wiggins, and G. F. Gibbons. 1999. Glucose phos-
phorylation is essential for the turnover of neutral lipid and the
second stage assembly of triacylglycerol-rich ApoB-containing lipo-
proteins in primary hepatocyte cultures. Arterioscler. Thromb. Vasc.
Biol. 19: 321–329.
25. Gibbons, G. F., S. M. Bartlett, C. E. Sparks, and J. D. Sparks. 1992.
Extracellular fatty acids are not utilized directly for the synthesis of
very-low-density lipoprotein in primary cultures of rat hepatocytes.
Biochem. J. 287: 749–753.
26. Schonfeld, G., and B. Pfleger. 1971. Utilization of exogenous free
fatty acids for the production of very low density lipoprotein tri-
glyceride by livers of carbohydrate-fed rats. J. Lipid Res. 12: 614–
621.
27. Hamilton, R. L., J. S. Wong, C. M. Cham, L. B. Nielsen, and S. G.
Young. 1998. Chylomicron-sized lipid particles are formed in the
setting of apolipoprotein B deficiency. J. Lipid Res. 39: 1543–1557.
28. Raabe, M., M. M. Veniant, M. A. Sullivan, C. H. Zlot, J. Bjorkegren,
L. B. Nielsen, J. S. Wong, R. L. Hamilton, and S. G. Young. 1999.
Analysis of the role of microsomal triglyceride transfer protein in the
liver of tissue-specific knockout mice. J. Clin. Invest. 103: 1287–1298.
29. Schonfeld, G., J. Ackerman, and D. Yablonskiy. 2001. Fatty liver in
familial hypobetalipoproteinemia (FHBL). Arterioscler. Thromb.
Vasc. Biol. 21: 656.
30. Yablonskiy, D. A., J. J. Ackerman, and G. Schonfeld. 2001. Liver-fat
 by guest, on August 17, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
478 Journal of Lipid Research Volume 44, 2003
content quantification by MR spectroscopy in patients with apoB
truncation-containing lipoproteins (Abstract). Radiology. 221: 496.
31. Bottomley, P. A. 1987. Spatial localization in NMR spectroscopy in
vivo. Ann. N. Y. Acad. Sci. 508: 333–348.
32. Raddi, A., and U. Klose. 1998. A generalized estimate of the SLR B
polynomial ripples for RF pulse generation. J. Magn. Reson. 132:
260–265.
33. Bretthorst, G. L. 1988. Bayesian Spectrum Analysis and Parameter
Estimation. Lecture Notus in Statistics. Springer-Verlag, Berlin.
34. Thomsen, C., U. Becker, K. Winkler, P. Christoffersen, M. Jensen,
and O. Henriksen. 1994. Quantification of liver fat using magnetic
resonance spectroscopy. Magn. Reson. Imaging. 12: 487–495.
35. Bligh, E., and W. Dyer. 1959. A rapid method of total lipid extrac-
tion and purification. Can. J. Biochem. Physiol. 37: 911–917.
36. Elias, N., B. W. Patterson, and G. Schonfeld. 1999. Decreased pro-
duction rates of VLDL triglycerides and ApoB-100 in subjects
heterozygous for familial hypobetalipoproteinemia. Arterioscler.
Thromb. Vasc. Biol. 19: 2714–2721.
37. Patterson, B. W., B. Mittendorfer, N. Elias, R. Satyanarayana, and
S. Klein. 2002. Use of stable isotopically labeled tracers to measure
very low density lipoprotein-triglyceride turnover. J. Lipid Res. 43:
223–233.
38. Elias, N., B. W. Patterson, and G. Schonfeld. 2000. In vivo metabo-
lism of ApoB, ApoA-I, and VLDL triglycerides in a form of hypo-
betalipoproteinemia not linked to the ApoB gene. Arterioscler.
Thromb. Vasc. Biol. 20: 1309–1315.
39. Hudgins, L. C., M. Hellerstein, C. Seidman, R. Neese, J. Diakun,
and J. Hirsch. 1996. Human fatty acid synthesis is stimulated by a
eucaloric low fat, high carbohydrate diet. J. Clin. Invest. 97: 2081–
2091.
40. Aarsland, A., and R. R. Wolfe. 1998. Hepatic secretion of VLDL
fatty acids during stimulated lipogenesis in men. J. Lipid Res. 39:
1280–1286.
41. Parks, E. J., R. M. Krauss, M. P. Christiansen, R. A. Neese, and
M. K. Hellerstein. 1999. Effects of a low-fat, high-carbohydrate diet
on VLDL-triglyceride assembly, production, and clearance. J. Clin.
Invest. 104: 1087–1096.
42. Lemieux, S., B. W. Patterson, A. Carpentier, G. F. Lewis, and G.
Steiner. 1999. A stable isotope method using a [(2)H(5)]glycerol
bolus to measure very low density lipoprotein triglyceride kinetics
in humans. J. Lipid Res. 40: 2111–2117.
43. Steele, R. 1959. Influences of glucose loading and of injected insu-
lin on hepatic glucose output. Ann. N. Y. Acad. Sci. 82: 420–430.
44. Rosenblatt, J., and R. R. Wolfe. 1988. Calculation of substrate flux
using stable isotopes. Am. J. Physiol. 254: E526–E531.
45. Matthews, D. R., J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F.
Treacher, and R. C. Turner. 1985. Homeostasis model assessment:
insulin resistance and beta-cell function from fasting plasma glu-
cose and insulin concentrations in man. Diabetologia. 28: 412–419.
46. Aguilar-Salinas, C. A., P. H. Barrett, K. G. Parhofer, S. G. Young, D.
Tessereau, J. Bateman, C. Quinn, and G. Schonfeld. 1995. Apopro-
tein B-100 production is decreased in subjects heterozygous for
truncations of apoprotein B. Arterioscler. Thromb. Vasc. Biol. 15: 71–80.
47. Welty, F. K., A. H. Lichtenstein, P. H. Barrett, G. G. Dolnikowski, J. M.
Ordovas, and E. J. Schaefer. 1997. Decreased production and in-
creased catabolism of apolipoprotein B-100 in apolipoprotein
B-67/B-100 heterozygotes. Arterioscler. Thromb. Vasc. Biol. 17: 881–888.
48. Parhofer, K. G., P. H. Barrett, C. A. Aguilar-Salinas, and G. Schon-
feld. 1996. Positive linear correlation between the length of trun-
cated apolipoprotein B and its secretion rate: in vivo studies in hu-
man apoB-89, apoB-75, apoB-54.8, and apoB-31 heterozygotes. J.
Lipid Res. 37: 844–852.
49. Groenewegen, W. A., M. R. Averna, J. Pulai, E. S. Krul, and G.
Schonfeld. 1994. Apolipoprotein B-38.9 does not associate with
apo[a] and forms two distinct HDL density particle populations
that are larger than HDL. J. Lipid Res. 35: 1012–1025.
50. Talmud, P. J., E. S. Krul, M. Pessah, G. Gay, G. Schonfeld, S. E.
Humphries, and R. Infante. 1994. Donor splice mutation gener-
ates a lipid-associated apolipoprotein B-27.6 in a patient with ho-
mozygous hypobetalipoproteinemia. J. Lipid Res. 35: 468–477.
51. Chen, Z., R. L. Fitzgerald, M. R. Averna, and G. Schonfeld. 2000. A
targeted apolipoprotein B-38.9-producing mutation causes fatty
livers in mice due to the reduced ability of apolipoprotein B-38.9
to transport triglycerides. J. Biol. Chem. 275: 32807–32815.
52. Chen, Z., R. L. Fitzgerald, and G. Schonfeld. 2002. Hypobetalipo-
proteinemic mice with a targeted apolipoprotein (Apo) B-27.6-
specifying mutation: in vivo evidence for an important role of
amino acids 1254–1744 of ApoB in lipid transport and metabolism
of the apoB-containing lipoprotein. J. Biol. Chem. 277: 14135–
14145.
53. Lin, X., G. Schonfeld, and Z. Chen. 2001. Molecular adaptation of
the fatty acid synthetic pathway to the presence of fatty livers in
gene-targeted mice producing apolipoprotein B-39.8 (Abstract).
Arterioscler. Thromb. Vasc. Biol. 21: 661.
54. Barter, P. J., and P. J. Nestel. 1973. Precursors of plasma triglycer-
ide fatty acids in obesity. Metabolism. 22: 779–783.
55. Barter, P. J., P. J. Nestel, and K. F. Carroll. 1972. Precursors of
plasma triglyceride fatty acid in humans. Effects of glucose con-
sumption, clofibrate administration, and alcoholic fatty liver. Me-
tabolism. 21: 117–124.
56. Pulai, J. I., H. Zakeri, P. Y. Kwok, J. H. Kim, J. Wu, and G. Schon-
feld. 1998. Donor splice mutation (665  1 G_T) in familial hypo-
betalipoproteinemia with no detectable apoB truncation. Am. J.
Med. Genet. 80: 218–220.
57. Wu, J., J. Kim, Q. Li, P. Y. Kwok, T.G. Cole, B. Cefalu, M. Averna,
and G. Schonfeld. 1999. Known mutations of apoB account for
only a small minority of hypobetalipoproteinemia. J. Lipid Res. 40:
955–959.
58. Yue, P., B. Yuan, D. S. Gerhard, R. J. Neuman, W. L. Isley, W. S.
Harris, and G. Schonfeld. 2002. Novel mutations of APOB cause
ApoB truncations undetectable in plasma and familial hypobetali-
poproteinemia. Hum. Mutat. 20: 110–116.
59. Young, S. G., S. T. Hubl, R. S. Smith, S. M. Snyder, and J. F. Terdi-
man. 1990. Familial hypobetalipoproteinemia caused by a muta-
tion in the apolipoprotein B gene that results in a truncated spe-
cies of apolipoprotein B (B-31). A unique mutation that helps to
define the portion of the apolipoprotein B molecule required for
the formation of buoyant, triglyceride-rich lipoproteins. J. Clin. In-
vest. 85: 933–942.
60. Groenewegen, W. A., E. S. Krul, and G. Schonfeld. 1993. Apolipo-
protein B-52 mutation associated with hypobetalipoproteinemia is
compatible with a misaligned pairing deletion mechanism. J. Lipid
Res. 34: 971–981.
61. Wagner, R. D., E. S. Krul, J. Tang, K. G. Parhofer, K. Garlock, P. Tal-
mud, and G. Schonfeld. 1991. ApoB-54.8, a truncated apolipopro-
tein found primarily in VLDL, is associated with a nonsense muta-
tion in the apoB gene and hypobetalipoproteinemia. J. Lipid Res.
32: 1001–1011.
62. Krul, E. S., K. G. Parhofer, P. H. Barrett, R. D. Wagner, and G.
Schonfeld. 1992. ApoB-75, a truncation of apolipoprotein B associ-
ated with familial hypobetalipoproteinemia: genetic and kinetic
studies. J. Lipid Res. 33: 1037–1050.
63. Talmud, P., L. King-Underwood, E. Krul, G. Schonfeld, and S.
Humphries. 1989. The molecular basis of truncated forms of apo-
lipoprotein B in a kindred with compound heterozygous hypobe-
talipoproteinemia. J. Lipid Res. 30: 1773–1779.
 by guest, on August 17, 2016
w
w
w
.jlr.org
D
ow
nloaded from
 
